Checkpoint inhibitor/interleukin‐based combination therapy of cancer
Abstract Background Immunotherapy using immune checkpoint inhibitors (ICIs) is the current focus in cancer immunotherapy. However, issues are raised in the area, as the recent studies showed that such therapeutic modality suffers from low durability and low or no efficacy for patients with some tumo...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4659 |
| _version_ | 1811309358851555328 |
|---|---|
| author | Keywan Mortezaee Jamal Majidpoor |
| author_facet | Keywan Mortezaee Jamal Majidpoor |
| author_sort | Keywan Mortezaee |
| collection | DOAJ |
| description | Abstract Background Immunotherapy using immune checkpoint inhibitors (ICIs) is the current focus in cancer immunotherapy. However, issues are raised in the area, as the recent studies showed that such therapeutic modality suffers from low durability and low or no efficacy for patients with some tumor types including cases with non‐inflamed or cold cancers. Therefore, efforts have been made to solve the issue using immune combination therapy, such as the use of immunocytokines. The combination of ICI with interleukins (ILs) and IL‐targeting agents is now under consideration in the area of therapy, and the primary results are promising. Purpose The focus of this review is to discuss the possibility of using ILs and IL‐targeting drugs in combination with ICI in cancer immunotherapy and describing recent advances in the field using PEGylated ILs and fusion proteins. The key focus in this area is to reduce adverse events and to increase the efficacy and durability of such combination therapy. |
| first_indexed | 2024-04-13T09:40:50Z |
| format | Article |
| id | doaj.art-4cf1637fb8fd47b39ab5a0384fed2501 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-13T09:40:50Z |
| publishDate | 2022-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-4cf1637fb8fd47b39ab5a0384fed25012022-12-22T02:51:56ZengWileyCancer Medicine2045-76342022-08-0111152934294310.1002/cam4.4659Checkpoint inhibitor/interleukin‐based combination therapy of cancerKeywan Mortezaee0Jamal Majidpoor1Department of Anatomy, School of Medicine Kurdistan University of Medical Sciences Sanandaj IranDepartment of Anatomy, Faculty of Medicine, Infectious Diseases Research Center Gonabad University of Medical Sciences Gonabad IranAbstract Background Immunotherapy using immune checkpoint inhibitors (ICIs) is the current focus in cancer immunotherapy. However, issues are raised in the area, as the recent studies showed that such therapeutic modality suffers from low durability and low or no efficacy for patients with some tumor types including cases with non‐inflamed or cold cancers. Therefore, efforts have been made to solve the issue using immune combination therapy, such as the use of immunocytokines. The combination of ICI with interleukins (ILs) and IL‐targeting agents is now under consideration in the area of therapy, and the primary results are promising. Purpose The focus of this review is to discuss the possibility of using ILs and IL‐targeting drugs in combination with ICI in cancer immunotherapy and describing recent advances in the field using PEGylated ILs and fusion proteins. The key focus in this area is to reduce adverse events and to increase the efficacy and durability of such combination therapy.https://doi.org/10.1002/cam4.4659combination therapyimmune checkpoint inhibitorinterleukinprogrammed death‐1 receptorprogrammed death‐ligand 1 |
| spellingShingle | Keywan Mortezaee Jamal Majidpoor Checkpoint inhibitor/interleukin‐based combination therapy of cancer Cancer Medicine combination therapy immune checkpoint inhibitor interleukin programmed death‐1 receptor programmed death‐ligand 1 |
| title | Checkpoint inhibitor/interleukin‐based combination therapy of cancer |
| title_full | Checkpoint inhibitor/interleukin‐based combination therapy of cancer |
| title_fullStr | Checkpoint inhibitor/interleukin‐based combination therapy of cancer |
| title_full_unstemmed | Checkpoint inhibitor/interleukin‐based combination therapy of cancer |
| title_short | Checkpoint inhibitor/interleukin‐based combination therapy of cancer |
| title_sort | checkpoint inhibitor interleukin based combination therapy of cancer |
| topic | combination therapy immune checkpoint inhibitor interleukin programmed death‐1 receptor programmed death‐ligand 1 |
| url | https://doi.org/10.1002/cam4.4659 |
| work_keys_str_mv | AT keywanmortezaee checkpointinhibitorinterleukinbasedcombinationtherapyofcancer AT jamalmajidpoor checkpointinhibitorinterleukinbasedcombinationtherapyofcancer |